(Reuters) – The National Institutes of Health said on Friday it has started a clinical study to test a combination of Gilead Sciences Inc’s antiviral drug remdesivir and anti-inflammatory drug baricitinib in COVID-19 patients.
The trial is currently enrolling adults hospitalized with COVID-19 in the United States and is expected to study the treatment combination in more than 1,000 participants. (https://bit.ly/2YM0tfp)
Baricitinib, which is marketed under brand name Olumiant by Eli Lilly and Co, was being tested as a potential treatment for hospitalized patients diagnosed with COVID-19.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Arun Koyyur)
